Scancell Share Discussion Threads

[plasybryn] 12/1/2019 19:00

I remain very encouraged by the potential here.Personal Cancer Vaccines like Modi-1 seem to be getting lots of energy behind them, but I'm also aware of the excitement around CART T - Adoptive Cell procedures. Do we have a view on which route will be the first to deliver a cancer cure, or is the Adoptive route too expensive given the white blood cells (T-Cells) have to be taken from the patient, then refrigerate and shipped to be reprogrammed using algorithms etc.Then frozen under liquid nitrogen before being transported back to the clinical site for infusion into the patient. But Co's like Adaptimmune, Cell Medica , Autolus and Free Therapeutics are all focused on cancer I believe.Any views please?

[drdobson1] 12/1/2019 16:49

Actually think his stake would be worth £300m.
I am not good with big numbers

[drdobson1] 12/1/2019 16:46

If the IDIOTT gets his £375 a Share he will be worth £100m OR if it stays at 8p he will be UBDERwater by £100,O00

Which is more likely ha ha ha ha

[drdobson1] 12/1/2019 16:08

Have you heard the latest PLUM duff from the Village Idiott
SCANcell should be a 150BILLION pound Company in his OPinion.THAT would make it WAIT FOR IT £375 A SHARE.
3000 shares would make me a millionaire
Makes his statement THAT we Have Already won Grand challenge a minor wrong orecuctiin.

Good JOb no one listens to his INANe Ramblings onnSCLPnand Brexit

Ha ha ha ha ha ha ha ha

[drdobson1] 11/1/2019 14:19

Classic comment fro Ray P the baNABA love child.
PhD students working with Lindy probably realise they are fortunate to be working with someone special.
Well others may OPINE that PhD students working with Failed Professor PLUM would be UNfortunate as he would STEAL their work and yes he is SPECIAL in his NEEDS just different

[torquayfan] 11/1/2019 11:07

Thanks for that Gooosed :-

''Jacob Plieth - ''Three times now during #JPM19 I've come across anti-PD-(L)1 being developed not for itself but just as a combo "tool".'' Dr. Zoidberg - ''We need a colloquial term for this type of approach. “Marriage drug”? “Alliance biologic”?''

How about ''Immunobody facilitator'' or ''vaccine prep'' ??

[torquayfan] 11/1/2019 00:06

These deals not new but here's an FB take on it. As Genentech increase their commitments to CAR-T here goes Sanofi with BioNTech themselves ?

''We start this week with two deals that illustrate the evolution of Sanofi's oncology R&D strategy. Sanofi centered its strategy on Regeneron when it struck a big deal with its longtime partner in 2015 but is now shifting its focus. The 2015 Regeneron deal is dead, replaced by an agreement that gives Sanofi an option on two assets but no discovery-stage relationship. Days before disclosing the news, Sanofi extended its cancer collaboration with BioNTech as part of a deal that saw it invest €80 million ($91 million) in the German mRNA specialist.

1. Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact

Sanofi is paying Regeneron $462 million (€404 million) to exit the immuno-oncology pact it formed in 2015. The move gives Sanofi the right to opt in to two bispecific programs but otherwise leaves each company free to operate independently.

2. Sanofi invests €80M in BioNTech as cancer mRNA hits clinic

Sanofi is set to invest €80 million ($91 million) in BioNTech and extend its cancer collaboration with the German mRNA specialist. The agreement comes as BioNTech and Sanofi prepare to start clinical development of the first cancer immunotherapy to emerge from their 2015 pact.''

[the real lozan] 10/1/2019 13:35

P S -
Always remember folks...there is =
"NO RISK here"

[torquayfan] 09/1/2019 22:57

OK Gazza thanks very much. (The memory holds up more or less but I wasn't around). I wondered what it was about - not much apparently. My 22.07 is still there.

[gazza] 09/1/2019 19:03

TF
>Sorry Gazza - what thread ? Where ?<<br />
Well if you missed it here's a recap:

Someone was going off on one about Brexit and treasury forecasts which he disparagingly said were done on a 486 dx66 machine.

One poster commented the rant must have been "booze fuelled".

Another said it is very unlike the individual in question to drink. I guess he does need drink to go on a rant.

Yet another poster asked whether he himself had done his (in)famous forecasts on the same computer?

The thread had gone by the time I looked the following morning probably because Brexit and treasury forecast are off topic.

Hope that fills in your missing knowledge (or memory!)

[bermudashorts] 09/1/2019 16:37

Panama but they're not preventing any deals on the Moditope platform as a whole - just the very specific area of TCR for Modi1 peptides which wouldn't even exist anyway without the collaboration.

[panama7] 09/1/2019 16:06

Bermuda, Biontech might well be paying for the collaboration but they are also preventing anyone else from having a look or doing a deal. If Scancell's tech is as brilliant as we are led to believe and we have significant interest as we are constantly told then our BOD should have got an upfront payment rather than continually expecting shareholders to pay their ever increasing salaries for which we have had no reward.

[bioking] 09/1/2019 14:17

OT) Please look at Futura Medical (FUM) has a dirt low market cap of 19 Million and has 3 Drugs including a potential MEGA Blockbuster in Phase 3 for the treatment of erectile dysfunction which works way faster than market leaders like Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[bermudashorts] 09/1/2019 14:04

Panama,

Don't want to get into a discussion over why Scancell haven't secured any licensing deals (other than SCIB2) but agree that it's frustrating and disappointing.

However, I don't think your comments regarding BioNtech and an upfront payment are justified or fair. It's not a licensing deal, just a simple collaboration. Scancell don't have the resources, expertise or manufacturing capabilities to develop a Moditope TCR and they need BioNtech. In return Scancell have simply granted them first dibs on a licensing deal - they haven't given away exclusive rights over the IP, just exclusivity over the option to license. If they decide to exercise that option then no doubt part of the package will be an up front payment.

At the stage they entered into the collaboration the product didn't exist, not even in a pre-clinical form - it was PRE pre-clinical if you like. BioNtech are very much paying for the option to license Modi1 TCR by diverting resources and spending hard research $$$ on the project. There is no way they would also pay an up front payment .

[torquayfan] 09/1/2019 13:58

Sorry Gazza - what thread ? Where ?

[panama7] 09/1/2019 13:19

Wigwammer, there have been all types of deals at all different stages of the Scientific cycle. We have had preclinical deals for far in excess of our Market Cap. We have been fobbed off by our board for 6 years with one excuse after another. Biontech have had an exclusivity option there should have been an upfront payment for that exclusivity. We have been told for 6 years there is significant interest in our platforms but not significant enough to get an upfront payment or one single deal on either platform. Goodfellow, Chiplin and Holloway all go back a long way they are more interested in lining each others pockets than rewarding their long suffering investors.

[wigwammer] 09/1/2019 11:26

Panama - I understand the frustration, but the deals being signed tend to be for assets further along the clinical path. It may well be that CH is right - that if they hadn't agreed to the TCR collaboration without fees then they would still be talking now. Instead, we have a situation where Biontech have spent a year investigating the potential, it's progressing well as LD confirmed at the AGM, and we are likely closer to commercialisation as a result.

[tosh123] 09/1/2019 10:48

Unfortunately Panama, what you say is the truth.
Its almost criminal.

[panama7] 09/1/2019 10:36

Tosh, yes £8 and now the share price drops below 8p. We have already seen in the first few days of the year billions of dollars spent on deals in the Immunotherapy market with upfront payments at multiples of our Market Cap. Holloway stated at the AGM to receive an upfront payment from Biontech for an exclusivity option would have meant we would still be talking, what a load of old rubbish, our BOD are incompetent beyond belief and must be one of the worse BOD's ever assembled in one Company. We have a trial that they have had 4 years to plan and can't even start it on time even when Trigrid 2 was given the go ahead to be used in trials a year ago. I have no idea why Investors are surprised at the performance of the share price it pretty much says everything we know about the BOD.

[tosh123] 09/1/2019 07:40

Best post of the day from the other place yesterday ;- " Inan, is that the same computer you used for your £8 in 6 months prediction "?

Made me laugh out loud.